Literature DB >> 20536934

Human stem cells as a model of motoneuron development and diseases.

Yan Liu1, Su-Chun Zhang.   

Abstract

Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) possess the potential to become all cell and tissue types of the human body. Under chemically defined culture systems, hESCs and hiPSCs have been efficiently directed to functional spinal motoneurons and astrocytes. The differentiation process faithfully recapitulates the developmental process predicted from studies in vertebrate animals and human specimens, suggesting the usefulness of stem cell differentiation systems in understanding human cellular development. Motoneurons and astrocytes differentiated from genetically altered hESCs or disease hiPSCs exhibit predicted phenotypes. They thus offer a simplified dynamic model for analyzing pathological processes that lead to human motoneuron degeneration, which in turn may serve as a template for pharmaceutical screening. In addition, the human stem cell-derived motoneurons and astrocytes, including those specifically derived from a patient, may become a source for cell therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536934      PMCID: PMC2885050          DOI: 10.1111/j.1749-6632.2010.05537.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  40 in total

1.  Control of synapse number by glia.

Authors:  E M Ullian; S K Sapperstein; K S Christopherson; B A Barres
Journal:  Science       Date:  2001-01-26       Impact factor: 47.728

Review 2.  Neuronal specification in the spinal cord: inductive signals and transcriptional codes.

Authors:  T M Jessell
Journal:  Nat Rev Genet       Date:  2000-10       Impact factor: 53.242

Review 3.  Cell replacement therapies for central nervous system disorders.

Authors:  A Björklund; O Lindvall
Journal:  Nat Neurosci       Date:  2000-06       Impact factor: 24.884

Review 4.  Defining glial cells during CNS development.

Authors:  S C Zhang
Journal:  Nat Rev Neurosci       Date:  2001-11       Impact factor: 34.870

5.  The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy.

Authors:  U R Monani; M Sendtner; D D Coovert; D W Parsons; C Andreassi; T T Le; S Jablonka; B Schrank; W Rossoll; W Rossol; T W Prior; G E Morris; A H Burghes
Journal:  Hum Mol Genet       Date:  2000-02-12       Impact factor: 6.150

6.  Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice.

Authors:  A M Clement; M D Nguyen; E A Roberts; M L Garcia; S Boillée; M Rule; A P McMahon; W Doucette; D Siwek; R J Ferrante; R H Brown; J-P Julien; L S B Goldstein; D W Cleveland
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

7.  Directed differentiation of embryonic stem cells into motor neurons.

Authors:  Hynek Wichterle; Ivo Lieberam; Jeffery A Porter; Thomas M Jessell
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

8.  A mouse model for spinal muscular atrophy.

Authors:  H M Hsieh-Li; J G Chang; Y J Jong; M H Wu; N M Wang; C H Tsai; H Li
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

9.  In vitro differentiation of transplantable neural precursors from human embryonic stem cells.

Authors:  S C Zhang; M Wernig; I D Duncan; O Brüstle; J A Thomson
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

10.  Homologous recombination in human embryonic stem cells.

Authors:  Thomas P Zwaka; James A Thomson
Journal:  Nat Biotechnol       Date:  2003-02-10       Impact factor: 54.908

View more
  7 in total

Review 1.  Neurological disorders and the potential role for stem cells as a therapy.

Authors:  Paul R Sanberg; David J Eve; L Eduardo Cruz; Cesar V Borlongan
Journal:  Br Med Bull       Date:  2012-02-21       Impact factor: 4.291

2.  Accelerated high-yield generation of limb-innervating motor neurons from human stem cells.

Authors:  Mackenzie W Amoroso; Gist F Croft; Damian J Williams; Sean O'Keeffe; Monica A Carrasco; Anne R Davis; Laurent Roybon; Derek H Oakley; Tom Maniatis; Christopher E Henderson; Hynek Wichterle
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

3.  Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells.

Authors:  Maria Teresa González-Garza; Héctor R Martínez; Enrique Caro-Osorio; Delia E Cruz-Vega; Martin Hernández-Torre; Jorge E Moreno-Cuevas
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

4.  Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.

Authors:  Bilada Bilican; Andrea Serio; Sami J Barmada; Agnes Lumi Nishimura; Gareth J Sullivan; Monica Carrasco; Hemali P Phatnani; Clare A Puddifoot; David Story; Judy Fletcher; In-Hyun Park; Brad A Friedman; George Q Daley; David J A Wyllie; Giles E Hardingham; Ian Wilmut; Steven Finkbeiner; Tom Maniatis; Christopher E Shaw; Siddharthan Chandran
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 5.  Induced pluripotent stem cells in the study of neurological diseases.

Authors:  Mario A Saporta; Marica Grskovic; John T Dimos
Journal:  Stem Cell Res Ther       Date:  2011-09-21       Impact factor: 6.832

6.  Large-Scale Production of Mature Neurons from Human Pluripotent Stem Cells in a Three-Dimensional Suspension Culture System.

Authors:  Alessandra Rigamonti; Giuliana G Repetti; Chicheng Sun; Feodor D Price; Danielle C Reny; Francesca Rapino; Karen Weisinger; Chen Benkler; Quinn P Peterson; Lance S Davidow; Emil M Hansson; Lee L Rubin
Journal:  Stem Cell Reports       Date:  2016-06-14       Impact factor: 7.765

Review 7.  ALS Patient Stem Cells for Unveiling Disease Signatures of Motoneuron Susceptibility: Perspectives on the Deadly Mitochondria, ER Stress and Calcium Triad.

Authors:  Anjoscha Kaus; Dhruv Sareen
Journal:  Front Cell Neurosci       Date:  2015-11-19       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.